Kane Biotech (TSXV:KNE) Cash-to-Debt : 0.09 (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Kane Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Kane Biotech's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.09.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Kane Biotech couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Kane Biotech's Cash-to-Debt or its related term are showing as below:

TSXV:KNE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.45 Max: No Debt
Current: 0.09

During the past 13 years, Kane Biotech's highest Cash to Debt Ratio was No Debt. The lowest was 0.08. And the median was 0.45.

TSXV:KNE's Cash-to-Debt is ranked worse than
95.14% of 1523 companies
in the Biotechnology industry
Industry Median: 6.46 vs TSXV:KNE: 0.09

Kane Biotech Cash-to-Debt Historical Data

The historical data trend for Kane Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kane Biotech Cash-to-Debt Chart

Kane Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

4.91

0.45

0.25

0.16

0.08

Kane Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.13	No Debt	0.18	0.08	0.09

Competitive Comparison of Kane Biotech's Cash-to-Debt

For the Biotechnology subindustry, Kane Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kane Biotech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Kane Biotech's Cash-to-Debt falls into.

Kane Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Kane Biotech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.749	/	(7.076	+	2.175)
	=	0.08

Kane Biotech's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.827	/	(7.132	+	2.065)
	=	0.09

Kane Biotech (TSXV:KNE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Kane Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Kane Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kane Biotech (TSXV:KNE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (TSXV:KNE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

KNBIF:USA

Address

290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2

Website

https://www.kanebiotech.com

Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, DermaKB and DermaKB Biofilm are trademarks of the company. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.

Executives

Philip Renaud

Director

Kane Biotech (TSXV:KNE) Headlines

No Headlines